Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies
S Cernea, KC Herold - Clinical immunology, 2010 - Elsevier
The way in which anti-CD3 monoclonal antibodies (mAbs) modify human immune
responses in type 1 diabetes (T1DM) is not known. We prepared a panel of Class I HLA-A2.
1 tetramers with peptides from diabetes-associated antigens and studied the frequency and
phenotype of the cells in patients with T1DM and blood donors and in patients treated with
anti-CD3 mAb (Teplizumab). More patients with T1DM showed positive staining for at least 1
tetramer using frozen and fresh samples (p< 0.05). Three months following treatment with …
responses in type 1 diabetes (T1DM) is not known. We prepared a panel of Class I HLA-A2.
1 tetramers with peptides from diabetes-associated antigens and studied the frequency and
phenotype of the cells in patients with T1DM and blood donors and in patients treated with
anti-CD3 mAb (Teplizumab). More patients with T1DM showed positive staining for at least 1
tetramer using frozen and fresh samples (p< 0.05). Three months following treatment with …